

REF. DOCTOR: SELF



PATIENT NAME: PALLAVI DHARMENDRA SINGH

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WD001243**

PATIENT ID: PALLF140486251 CLIENT PATIENT ID: 012304140074

ABHA NO :

AGE/SEX :37 Years Female
DRAWN :14/04/2023 10:47:00
RECEIVED :14/04/2023 11:58:54
REPORTED :15/04/2023 19:46:42

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BI	LOW 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	11.7 Low	12.0 - 15.0	g/dL
METHOD: CYANIDE FREE DETERMINATION			
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	3.93	3.8 - 4.8	mi l /μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	6.70	4.0 - 10.0	thou/μL
PLATELET COUNT	182	150 - 410	thou/µL
METHOD : ELECTRONIC IMPEDANCE	102	130 - 410	τησα, με
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	35.3 Low	36 - 46	%
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	90.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	29.9	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	33.3	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	14.2 High	11.6 - 14.0	%
METHOD: CALCULATED PARAMETER			
MENTZER INDEX	22.9		
MEAN PLATELET VOLUME (MPV)	10.4	6.8 - 10.9	fL
METHOD: CALCULATED PARAMETER			
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	50	40 - 80	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
LYMPHOCYTES	43 High	20 - 40	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY MONOCYTES	05	2 - 10	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	U.J	2 - 10	/U
EOSINOPHILS	02	1 - 6	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			

Dr. Akansha Jain Consultant Pathologist





Page 1 Of 12

View Details









PATIENT NAME: PALLAVI DHARMENDRA SINGH REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WD001243 PATIENT ID : PALLF140486251

CLIENT PATIENT ID: 012304140074

ABHA NO

AGE/SEX :37 Years Female DRAWN :14/04/2023 10:47:00 RECEIVED: 14/04/2023 11:58:54 REPORTED :15/04/2023 19:46:42

	<u> </u>		
Test Report Status <u>Preliminary</u>	Results	Biological Reference	Interval Units
BASOPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	00	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED PARAMETER	3.35	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED PARAMETER	2.88	1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT METHOD: CALCULATED PARAMETER	0.34	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD: CALCULATED PARAMETER	0.13	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.2		

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain Consultant Pathologist





Page 2 Of 12

Patient Ref. No. 775000002907337





PATIENT NAME: PALLAVI DHARMENDRA SINGH REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WD001243 PATIENT ID : PALLF140486251

CLIENT PATIENT ID: 012304140074

ABHA NO

AGE/SEX :37 Years Female :14/04/2023 10:47:00 DRAWN RECEIVED: 14/04/2023 11:58:54

REPORTED :15/04/2023 19:46:42

Test Report Status Results **Biological Reference Interval** Units **Preliminary**

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R 0 - 20mm at 1 hr

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Akansha Jain Consultant Pathologist



Page 3 Of 12







Create PDF without Trial Waterm Diagnostics

REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

PATIENT NAME: PALLAVI DHARMENDRA SINGH

JAIPUR 302017 9314660100

ACCESSION NO: 0251WD001243 PATIENT ID : PALLF140486251

CLIENT PATIENT ID: 012304140074 ABHA NO

AGE/SEX :37 Years Female DRAWN :14/04/2023 10:47:00 RECEIVED: 14/04/2023 11:58:54 REPORTED :15/04/2023 19:46:42

Test Report Status Results **Biological Reference Interval** Units **Preliminary**

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE O

METHOD: TUBE AGGLUTINATION

RH TYPE **POSITIVE**

METHOD: TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain Consultant Pathologist Page 4 Of 12









PATIENT NAME: PALLAVI DHARMENDRA SINGH

REF. DOCTOR: SELF ACCESSION NO: 0251WD001243 AGE/SEX

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

PATIENT ID : PALLF140486251

CLIENT PATIENT ID: 012304140074

RECEIVED: 14/04/2023 11:58:54

:14/04/2023 10:47:00

:37 Years

DRAWN

Female

9314660100

ABHA NO

REPORTED :15/04/2023 19:46:42

Biological Reference Interval Units Test Report Status Results **Preliminary**

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 83 74 - 99 mg/dL

METHOD: GLUCOSE OXIDASE

JAIPUR 302017

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

HBA1C 5.3 Non-diabetic: < 5.7 %

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) 105.4 < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

GLUCOSE, POST-PRANDIAL, PLASMA

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL 143 < 200 Desirable mg/dL 200 - 239 Borderline High

>/= 240 High

RESULT PENDING

TRIGLYCERIDES mg/dL 111 < 150 Normal

150 - 199 Borderline High

200 **-** 499 High >/=500 Very High

HDL CHOLESTEROL 42 < 40 Low mg/dL

>/=60 High

< 100 Optimal CHOLESTEROL LDL 79 mg/dL

100 - 129

Near optimal/ above optimal

130 - 159 Borderline High 160 - 189 High >/= 190 Very High

Dr. Akansha Jain Consultant Pathologist



Page 5 Of 12



MC-5333 **REF. DOCTOR:** SELF

PATIENT NAME: PALLAVI DHARMENDRA SINGH

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WD001243

: PALLF140486251

CLIENT PATIENT ID: 012304140074

ABHA NO

PATIENT ID

AGE/SEX :37 Years Female :14/04/2023 10:47:00 DRAWN RECEIVED: 14/04/2023 11:58:54 REPORTED :15/04/2023 19:46:42

Test Report Status <u>Preliminary</u>	Results	Biological Reference Interval Units	
NON HDL CHOLESTEROL	101	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	
VERY LOW DENSITY LIPOPROTEIN	22.2	= 30.0</math mg/dL	
CHOL/HDL RATIO	3.4	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	1.9	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL	0.57	0 - 1 mg/dL	
BILIRUBIN, DIRECT	0.20	0.00 - 0.25 mg/dL	
BILIRUBIN, INDIRECT	0.37	0.1 - 1.0 mg/dL	
TOTAL PROTEIN	7.4	6.4 - 8.2 g/dL	
ALBUMIN	4.3	3.8 - 4.4 g/dL	
GLOBULIN	3.1	2.0 - 4.1 g/dL	
ALBUMIN/GLOBULIN RATIO	1.4	1.0 - 2.1 RATIO	
ASPARTATE AMINOTRANSFERASE(AST/SGOT) 19	0 - 31 U/L	
ALANINE AMINOTRANSFERASE (ALT/SGPT)	14	0 - 31 U/L	
ALKALINE PHOSPHATASE	70	39 - 117 U/L	
GAMMA GLUTAMYL TRANSFERASE (GGT)	9	7 - 32 U/L	
LACTATE DEHYDROGENASE	390	230 - 460 U/L	
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	12	5.0 - 18.0 mg/dL	
CREATININE, SERUM			
CREATININE	0.87	0.6 - 1.2 mg/dL	
BUN/CREAT RATIO			



SRL Ltd

Dr. Akansha Jain **Consultant Pathologist**





Page 6 Of 12

PERFORMED AT:

Rajasthan, INDIA



REF. DOCTOR: SELF

PATIENT NAME: PALLAVI DHARMENDRA SINGH

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WD001243 PATIENT ID : PALLF140486251

CLIENT PATIENT ID: 012304140074

ABHA NO

AGE/SEX :37 Years Female DRAWN :14/04/2023 10:47:00 RECEIVED: 14/04/2023 11:58:54 REPORTED :15/04/2023 19:46:42

Test Report Status	<u>Preliminary</u>	Results	Biological Reference	ce Interval Units
BUN/CREAT RATIO		13.79		
URIC ACID, SERUM				
URIC ACID		5.0	2.4 - 5.7	mg/dL
TOTAL PROTEIN, SERU	IM			
TOTAL PROTEIN		7.4	6.4 - 8.3	g/dL
ALBUMIN, SERUM				
ALBUMIN		4.3	3.8 - 4.4	g/dL
GLOBULIN				
GLOBULIN		3.1	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K	/CL), SERUM			
SODIUM, SERUM		145.0	137 - 145	mmo l /L
POTASSIUM, SERUM		4.17	3.6 - 5.0	mmol/L
CHLORIDE, SERUM		106.2	98 - 107	mmol/L

Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical in sufficiency, hypopituitarism, diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients. 2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
- eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates

addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

Dr. Akansha Jain

Consultant Pathologist





Page 7 Of 12

View Report

PERFORMED AT:



MC-5333 **REF. DOCTOR: SELF**

PATIENT NAME: PALLAVI DHARMENDRA SINGH

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WD001243

PATIENT ID : PALLF140486251

CLIENT PATIENT ID: 012304140074

RECEIVED: 14/04/2023 11:58:54

:14/04/2023 10:47:00

:37 Years

Female

REPORTED: 15/04/2023 19:46:42

Test Report Status Preliminary Results

ABHA NO

Biological Reference Interval Units

AGE/SEX

DRAWN

- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive

liver disease,high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein,is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUMHuman serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Akansha Jain Consultant Pathologist Page 8 Of 12





View Report



PATIENT NAME: PALLAVI DHARMENDRA SINGH REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WD001243**PATIENT ID : PALLF140486251

CLIENT PATIENT ID: 012304140074

ABHA NO :

AGE/SEX :37 Years Female
DRAWN :14/04/2023 10:47:00
RECEIVED :14/04/2023 11:58:54
REPORTED :15/04/2023 19:46:42

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

PH 5.5 4.7 - 7.5SPECIFIC GRAVITY 1.003 - 1.035 1.010 **PROTEIN NOT DETECTED NOT DETECTED GLUCOSE** NOT DETECTED NOT DETECTED **KETONES NOT DETECTED NOT DETECTED BLOOD** NOT DETECTED NOT DETECTED **BILIRUBIN** NOT DETECTED NOT DETECTED **UROBILINOGEN NORMAL NORMAL NITRITE NOT DETECTED NOT DETECTED** LEUKOCYTE ESTERASE **NOT DETECTED NOT DETECTED**

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF

PUS CELL (WBC'S)

1-2

0-5

/HPF

EPITHELIAL CELLS

3-5

0-5

/HPF

CASTS NOT DETECTED CRYSTALS NOT DETECTED

BACTERIA NOT DETECTED NOT DETECTED
YEAST NOT DETECTED NOT DETECTED

Dr. Akansha Jain Consultant Pathologist Page 9 Of 12











PATIENT NAME: PALLAVI DHARMENDRA SINGH

CODE/NAME & ADDRESS: C000049066
SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 REF. DOCTOR: SELF
ACCESSION NO: 0251WD001243 AGE

PATIENT ID : PALLF140486251

CLIENT PATIENT ID: 012304140074

ABHA NO

AGE/SEX :37 Years Female DRAWN :14/04/2023 10:47:00

RECEIVED : 14/04/2023 11:58:54 REPORTED :15/04/2023 19:46:42

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD SAMPLE NOT RECEIVED

Dr. Akansha Jain Consultant Pathologist Page 10 Of 12





View Details

Miew Depart





PATIENT NAME: PALLAVI DHARMENDRA SINGH

CODE/NAME & ADDRESS: C000049066
SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 REF. DOCTOR: SELF
ACCESSION NO: 0251WD001243 AGE

PATIENT ID : PALLF140486251

CLIENT PATIENT ID: 012304140074

ABHA NO :

AGE/SEX :37 Years Female
DRAWN :14/04/2023 10:47:00

PECEIVED :14/04/2023 11:58:54

RECEIVED : 14/04/2023 11:58:54 REPORTED :15/04/2023 19:46:42

Test Report Status Preliminary

Results

Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, STOOL

COLOUR SAMPLE NOT RECEIVED

N. British Stande

Dr. Abhishek Sharma Consultant Microbiologist





Page 11 Of 12

View Details

PERFORMED AT:







PATIENT NAME: PALLAVI DHARMENDRA SINGH REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WD001243**PATIENT ID : PALLF140486251

CLIENT PATIENT ID: 012304140074

ABHA NO :

AGE/SEX :37 Years Female
DRAWN :14/04/2023 10:47:00
RECEIVED :14/04/2023 11:58:54
REPORTED :15/04/2023 19:46:42

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

T3 114.54 60.0 - 181.0 ng/dL T4 **11.70 High** 4.5 - 10.9 μ g/dL TSH (ULTRASENSITIVE) 1.702 0.550 - 4.780 μ IU/mL

End Of Report
Please visit www.sr|world.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Akansha Jain

Consultant Pathologist





Page 12 Of 12

View Details







akriti Labs

3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com CIN No. U85195RJ2004PTC019563



Name

: Mrs. PALLAVI DHARMENDRA SINGH

Age/Gender: 37 Y/Female Patient ID : 012304140074

BarcodeNo:10082480

Referred By: Self

Registration No: 55866

Registered

: 14/Apr/2023 10:47AM

Analysed

: 14/Apr/2023 01:53PM

Reported

: 14/Apr/2023 01:53PM

Panel

: MEDI WHEEL (ARCOFEMI

HEALTHCARE LTD)

USG: WHOLE ABDOMEN (Female)

LIVER

: Is normal in size and shape with mild bright echogenecity.

The IHBR and hepatic radicals are not dilated. No evidence of focal echopoor/echorich lesion seen. Portal vein diameter and Common bile duct normal in size

GALL

: Is normal in size, shape and echotexture. Walls are smooth and

BLADDER regular with normal thickness. There is no evidence of cholelithiasis.

PANCREAS: Is normal in size, shape and echotexture. Pancreatic duct is not dilated. SPLEEN : Is normal in size, shape and echogenecity. Spleenic hilum is not dilated.

KIDNEYS : Bilateral Kidneys are normal in size, shape and echotexture,

corticomedullary differentiation is fair and ratio appears normal.

Pelvi calyceal system is normal.No evidence of hydronephrosis/ nephrolithiasis.

URINARY : Bladder is partially filled as patient not willing to hold urine.

BLADDER: Pre void vol: 75 ml

UTERUS: Uterus and ovaries could not be seen due to partially filled bladder

SPECIFIC: No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.

NO evidence of lymphadenopathy or mass lesion in retroperitoneum. Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION: Mild fatty liver

*** End Of Report ***

Page 1 of 1



Dr. Neera Mehta M.B.B.S., D.M.R.D. RMCNO.005807/14853



akriti Labs

3. Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com CIN No. U85195RJ2004PTC019563



: Mrs. PALLAVI DHARMENDRA SINGH

Age/Gender: 37 Y/Female

Patient ID : 012304140074

BarcodeNo: 10082480

Referred By: Self

Registration No: 55866

Registered

Reported

: 14/Apr/2023 10:47AM

Analysed

: 15/Apr/2023 11:44AM

Panel

: 15/Apr/2023 11:44AM : MEDI WHEEL (ARCOFEMI

HEALTHCARE LTD)

DIGITAL X-RAY CHEST PA VIEW

Metallic artifacts are seen.

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle are clear.

Domes of diaphragm are normally placed.


Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

*** End Of Report ***

Page 1 of 1

Dr. Negra Mehta M.B.B.S., D.M.R.D. RMCNO.005807/14853





Aakriti Labs

3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com CIN No. U85195RJ2004PTC019563

NAME	MRS PALLAVI DHARMENDRA SINGH	AGE	37Y	SEX	FEMALE
REF BY	TOWARD CONTRACTOR		The state of the s	REG NO	

ECHOCARDIOGRAM REPORT

WINDOW-POOR/	ADEQUATE.	/GOODVALVE
--------------	-----------	------------

MITRAL	NORMAL	TRICUSPID	NORMAL	
AORTIC	NORMAL	PULMONARY	NORMAL	

2D/M-MOD

IVSD mm	8.5	IVSS mm	10.1	AORTA mm	28.8
LVID mm	40.6	LVIS mm	26.7	LA mm	30.8
LVPWD mm	8.8	LVPWS mm	10.1	EF%	60%

CHAMBERS

LA	NORMAL	RA	NORMAL
LV	NORMAL	RV	NORMAL
PERICARDIUM	NORMAL		

DOPPLER STUDY MITRAL

PEAK VELOCITY m/s E/A	0.69/0.56	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	<u> </u>
MVA cm2 (PLANITMETERY)		MVA cm2 (PHT)	/600 (602 (603 (603
MR			9

AORTIC

PEAK VELOCITY m/s	1.74	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
AR			

TRICUSPID

PEAK VELOCITY m/s	0.79	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
TR		PASP mmHg	

PULMONARY

PULIVIONANT			
PEAK VELOCITY m/s	1.42	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
PR		RVEDP mmHg	

IMPRESSION

- NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION
- NO RWMA LVEF 60%
- NORMAL RV FUNCTION
- NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL

CONCLUSION: FAIR LV FUNCTION.

Cardiologist



Aakriti Labs

3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com CIN No. U85195RJ2004PTC019563



Name - Pallavi Age - 37/F Address - Jaipur

Vm 6/9

Refraction:
R -> - 0:50 >> h

L -> -0:75 -> ph.

Colour Vision MADellness Andus - NADPAITNEI



